Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
ABBV
ABBV
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ABBV News
Biotech Sector Sees FDA Approvals and Layoffs
17h ago
NASDAQ.COM
AbbVie Declares Quarterly Cash Dividend of $1.73
1d ago
PRnewswire
IWF Stock Price Analysis and ETF Dynamics
1d ago
NASDAQ.COM
AbbVie Receives FDA Approval for New Neck Anti-Wrinkle Product
3d ago
seekingalpha
SKINVIVE by JUVÉDERM Receives FDA Approval for Neck Treatment
3d ago
NASDAQ.COM
FDA Approves SKINVIVE by JUVÉDERM for Neck Wrinkles
3d ago
NASDAQ.COM
Conexeu Sciences Expands Board to Support Commercialization Efforts
3d ago
PRnewswire
SKINVIVE by JUVÉDERM® Receives FDA Approval for Neck Wrinkles
3d ago
Newsfilter
AbbVie, Chevron, and Enterprise Products' Dividend Prospects
4d ago
NASDAQ.COM
Top High-Yield Dividend Stocks: AbbVie, Chevron, Enterprise
4d ago
Fool
Teva Pharmaceutical's Recovery: Challenges and Opportunities in Biosimilars
Jun 12 2026
Fool
AbbVie Showcases New Data in Blood Cancer Portfolio
Jun 12 2026
Fool
AbbVie Expands Blood Cancer Treatment Market with New Data
Jun 12 2026
NASDAQ.COM
AbbVie Presents Landmark Nine-Year CLL14 Trial Results
Jun 12 2026
NASDAQ.COM
AbbVie Unveils New Phase 3 Data on Venetoclax for CLL at EHA 2026
Jun 12 2026
PRnewswire
AbbVie Reveals Phase 3 CLL14 Trial Data at EHA 2026
Jun 12 2026
PRnewswire
Show More News
